Connect with us

Press Release

New Clinical Data Reveals MAIA Biotechnology’s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Published

on

–News Direct–

By Mangeet Kaur Bouns

Lung cancer remains the top cause of cancer-related deaths in the U.S., accounting for approximately 20% of all cancer fatalities. The American Cancer Society's projections for 2024 highlight the gravity of this issue, with an estimated 234,580 new lung cancer cases and about 125,070 deaths anticipated in the U.S. Of these, nearly 80% to 85% are non-small cell lung cancer (NSCLC) cases, highlighting the urgent need for effective treatments.

MAIA Biotechnology, Inc. (AMEX: MAIA), a clinical-stage biopharmaceutical company focused on developing telomere-targeting immunotherapies for cancer treatment, has unveiled promising new clinical data showcasing the efficacy of its lead product candidate, THIO, in treating NSCLC. This data emerges from a phase 2 clinical trial evaluating THIO in combination with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo), targeting patients with advanced NSCLC who have not responded to at least two standard-of-care therapies.

In the context of NSCLC, where traditional treatments often fall short, THIO's potential as a first-in-class telomere-targeting agent raises hope. Its ability to disrupt cancer cell telomeres and stimulate immune responses marks a significant advancement in the fight against this devastating disease.

MAIAs Lead Candidate: THIO

THIO is a groundbreaking telomere-targeting agent, currently undergoing phase 2 clinical trials aimed at treating NSCLC with telomerase-positive cancer cells. Telomerase, present in over 85% of human cancers, plays a crucial role in the immortality and proliferation of cancer cells. THIO integrates into telomeres within these cells, disrupting their structure and function leading to rapid tumor cell death.

By inducing telomerase-dependent DNA modification and damage, THIO triggers selective cancer cell death. This process accumulates telomeric damage in cytosolic micronuclei, which then activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. In in vivo cancer models, sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in significant and sustained tumor regression, fostering cancer-specific immune memory.

Key Findings From The Phase 2 THIO-101 Clinical Trial

The phase 2 THIO-101 trial primarily focuses on assessing the safety and tolerability of THIO both as an anticancer agent and as an immune system activator, alongside evaluating its clinical efficacy through overall response rate (ORR).

The trial results are noteworthy. The disease control rate (DCR) for THIO in combination with CPI was 85%, far exceeding the 25-35% DCR typically seen with chemotherapy in third-line treatments. Additionally, 65% of patients surpassed the 5.8-month overall survival (OS) threshold, and 85% exceeded the 2.5-month progression-free survival (PFS) threshold, demonstrating significant clinical benefits. The median survival follow-up time stood at 9.1 months for the cohort of 20 patients.

Optimal dose selection yielded even more impressive outcomes. Patients in third-line receiving 180mg of THIO exhibited a median PFS of 5.5 months, a 75% OS rate at six months and an ORR of 38%, compared to the standard 6-10% ORR for chemotherapy. Notably, 75% of these patients crossed the 5.8-month OS threshold and 88% surpassed the 2.5-month PFS threshold, with a median survival follow-up time of 9.1 months among the eight patients assessed.

Implications And Future Directions

Dr. Vlad Vitoc, chairman and CEO of MAIA, expressed enthusiasm about the trial outcomes, noting, "All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard-of-care treatments." He emphasized THIOs potential as a robust, safe and highly effective alternative for patients who have not benefited from chemotherapy and other treatments.

The THIO-101 trial, which completed enrollment ahead of schedule in February, reached its target of 41 patients for the 180 mg dose. This data, which indicates promising disease control and overall response rates, paves the way for further investigation and potential redefinition of cancer treatment protocols.

As THIO-101 data continues to demonstrate favorable disease control and response rates, with full efficacy data anticipated in the latter half of this year, MAIA Biotechnology stands poised to redefine cancer treatment. THIOs promise to transform the standard of care in oncology offers new hope to patients with advanced NSCLC, potentially establishing a new benchmark in cancer therapy.

Featured photo by CI Photos at Shutterstock.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/new-clinical-data-reveals-maia-biotechnologys-thio-achieves-high-efficacy-in-advanced-non-small-cell-lung-cancer-treatment-599831106

Benzinga

comtex tracking

COMTEX_453480766/2655/2024-06-07T08:20:02

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

DemanPlay Surpasses 200,000 Discord Community Members, Expanding Its Chinese Gaming Community Ecosystem in NA

Published

on

United States, 19th Mar 2026DemanPlay, a Chinese gaming community in NA, announced that as of March 15, 2026, the total number of members across its Discord communities has officially surpassed 200,000, marking a major milestone in its long-term growth.

According to the platform’s latest internal data, approximately 30% of its community users are located in Canada and 62% are based in the United States, based on IP address distribution across its online community. The remaining users mainly come from regions including Europe and Australia. The platform continues to grow steadily, adding around 3,500 new users per month and attracting Chinese-speaking gamers from across Canada and the U.S.

As its community continues to expand, DemanPlay has further strengthened its presence in gaming social networking, team matchmaking, interactive companionship services, and diversified online entertainment. Since its founding in 2018, DemanPlay has operated steadily for eight years, gradually building a mature and scalable community ecosystem.

One of DemanPlay’s core strengths is its response efficiency. Based on internal platform data, the average response time from a user placing an order to someone accepting it is under five seconds across all supported game categories. This reflects the platform’s continued advantage in both activity level and matchmaking speed.

In addition to fast response and matchmaking, DemanPlay has established a unified recharge and account system that allows users to recharge once and use their balance across multiple services within the community. These services include, but are not limited to, account rentals, in-game item trading, and other interactive gaming-related services. The platform also operates an automated after-sales system and 24/7 customer support, providing users with a stable and efficient service experience.
 

At present, DemanPlay’s main community covers multiple popular game sections, including:

  • League of Legends
  • VALORANT
  • CS2
  • PUBG

In addition, the platform also operates a dedicated Delta Force international server community, further meeting the social and matchmaking needs of different player groups.

Beyond gaming itself, DemanPlay continues to expand its community content ecosystem with a range of lifestyle and interest-based sections, including player selfie sharing, job information exchange, astrology discussions, and car and model collecting. These features help users build more authentic and engaging connections outside of gaming.

In terms of service coverage, DemanPlay currently supports multiple popular titles and interactive entertainment categories, including but not limited to:

  • League of Legends (NA)
  • VALORANT (NA)
  • CS2 (NA)
  • Delta Force (CN and International)
  • Teamfight Tactics (NA)
  • Overwatch 2 (NA)
  • APEX Legends (NA)

 

The platform also offers entertainment-based interactive services such as music request sessions, Werewolf-style social games, and Goose Goose Duck, creating a more diversified online entertainment experience for users.

Beyond community operations and service infrastructure, DemanPlay’s North American team Deman Esport has also delivered strong competitive results. In 2024, Deman Esport won the championship in the North America Grand Final of the Naraka: Bladepoint Koi Cup, demonstrating the competitive strength of both its player community and team structure.

Ria Li said that reaching 200,000 users is not only a milestone for the community, but also a reflection of the growing demand among Chinese gamers in North America for high-quality online gaming communities and interactive services.

Daniel Hu said the platform will continue to improve its technical capabilities and user service systems while expanding into more game categories and community interaction scenarios.

Aaron Wan said DemanPlay will continue to strengthen its brand presence and community-building capabilities, with the goal of creating a more welcoming, active, and engaging environment for Chinese gamers across North America.

As one of the important Chinese online gaming communities in North America, DemanPlay will continue to invest in community experience, service efficiency, and content expansion, providing a richer, faster, and more interactive entertainment environment for gamers across the region.

Media Contact

Organization: Demanplay

Contact Person: Aaron Wan

Website: http://demanplay.com/

Email: Send Email

Country:United States

Release id:42736

The post DemanPlay Surpasses 200,000 Discord Community Members, Expanding Its Chinese Gaming Community Ecosystem in NA appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Pioneering Psychedelic Harm Reduction: Mushrooms.support Bridges the Gap Between Colorado’s Legal Reforms and Evidence-Based Psilocybin and DMT Education

Published

on

DENVER, COLORADO – March 18, 2026 – As Colorado continues to lead the nation in progressive psychedelic legislation under the Natural Medicine Health Act (NMHA), a groundbreaking Denver-based platform is setting the global standard for safety, education, and integration. Mushrooms.support, operating under Lyman Support Centers LLC, has officially announced the expansion of its comprehensive ecosystem dedicated to harm reduction, non-commercial gifting, and guided support for adults exploring the therapeutic benefits of psilocybin and dimethyltryptamine (DMT).
Following the historic voter approval of Proposition 122 and subsequent SB23-290 refinements, Colorado decriminalized the personal use, possession, and sharing of natural medicines for adults over 21. Navigating this new legal landscape, Mushrooms.support emerges as a vital community hub. Operating strictly within the non-commercial parameters of the law, the platform facilitates the free gifting of psilocybin and DMT while offering paid, professionally guided harm reduction sessions ranging from an accessible $10 to $200. This model ensures that life-changing mental health support and safety are accessible to all demographics, effectively removing the financial barriers often associated with psychedelic-assisted care.
The Scientific Foundation of Therapeutic Psychedelics The platform’s mission is deeply rooted in cutting-edge clinical research. Recent phase III trials and landmark studies from institutions like Johns Hopkins University have demonstrated the profound efficacy of psilocybin in treating Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), and end-of-life existential anxiety.
By acting as a serotonin 5-HT2A receptor agonist, psilocybin promotes neuroplasticity, helping to rewire maladaptive thought patterns. Similarly, emerging research highlights endogenous DMT’s potential as a rapid-acting antidepressant and neuroprotectant. Mushrooms.support translates this complex science into actionable guidance for individuals dealing with PTSD, OCD, cluster headaches, and substance use disorders.

Award-Winning Harm Reduction Principles Recognized as the “Psychedelic Cup 2025 Winner” and awarded “Most Homogeneous” for its consistent quality and safety standards, Mushrooms.support distinguishes itself through five core principles of harm reduction:
1.    Rigorous Testing: Ensuring the purity and safety of natural medicines.
2.    Comprehensive Education: Providing transparent data on physiological effects and risks.
3.    Set and Setting Preparation: Guiding users to create optimal environments for psychological safety.
4.    On-Site Guided Support: Offering trained presence during the experience.
5.    Post-Experience Integration: Helping users process and apply their insights for long-term personal growth.
Trained ambassadors and medical referrals are available to ensure that every individual’s journey is safe and therapeutically beneficial. The platform also strictly educates on contraindications, prominently warning against the risks of serotonin syndrome for individuals on specific medications or those with underlying cardiovascular or psychotic conditions.
“Decriminalization is only the first step; the true evolution of mental health care requires a solid foundation of safety, education, and community support,” says Darren Lyman, founder of Mushrooms.support and author of foundational texts on psychedelic integration. “Our goal is to transform Colorado’s legal framework into a scientifically grounded, accessible public health strategy. We are providing the essential resources—from microdosing guides to post-session integration—so individuals can explore these powerful natural medicines without fear or stigma.”
 

A Comprehensive Community Ecosystem Beyond one-on-one support, the Denver facility (located at 800 W. 8th Ave #110) and its digital platform offer an expansive library of resources. Users can access microdosing protocols, integration workbooks, specialized PDF drink recipes, chocolate formulations, and connections to trusted community growers and wellness products like Epic Balms.
As the psychedelic renaissance accelerates in 2026, Mushrooms.support stands at the forefront of the movement, ensuring that the integration of psilocybin and DMT into mainstream wellness is conducted ethically, safely, and equitably.
For more information, to access harm reduction resources, or to schedule a session, visit Website.

About Mushrooms.support

Mushrooms.support is a Denver-based educational and harm reduction platform operating under the Colorado Natural Medicine Health Act. Founded by Darren Lyman and managed by Lyman Support Centers LLC, the center provides non-commercial gifting of natural medicines alongside expert-guided support, integration services, and scientific resources for adults 21 and older. Operations run Tuesday through Saturday from 2:00 PM to 6:45 PM.

 

Media Contact

Organization: Redpresswire

Contact Person: Gorkem

Website: https://redpress.net

Email: Send Email

Contact Number: +905451552424

Address:Suite 10560 5 Brayford Square

City: London

Country:United Kingdom

Release id:42791

Disclaimer: This press release is for informational purposes only. Statements regarding therapeutic effects of psilocybin and DMT are based on research and do not constitute medical advice. Individuals should consult qualified healthcare professionals before using these substances.

The post Pioneering Psychedelic Harm Reduction: Mushrooms.support Bridges the Gap Between Colorado’s Legal Reforms and Evidence-Based Psilocybin and DMT Education appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards

Published

on

BiFinance, a leading Web3 digital asset trading platform, has officially announced the listing of EVOCARE (EVOCARE) and the launch of a dedicated trading competition, offering users multiple participation opportunities and enhanced engagement.

EVOCARE Officially Listed on BiFinance

According to the official announcement, BiFinance has listed the EVOCARE USDT trading pair, with deposit and trading services opened on March 12, 2026.

EVOCARE represents an innovative Web3 healthcare initiative focused on building a digital therapy ecosystem. As The World Therapy Store, EvoCare aims to connect patients, therapists, and healthcare creators through a scalable and compliant infrastructure, integrating real-world medical services with blockchain technology and bringing real-world utility into the Web3 space.

The platform combines regulated healthcare services with Web3 utility infrastructure, creating a scalable global ecosystem for therapy, rehabilitation, and digital health services. EvoCare is designed to enable German-quality therapeutic care to be delivered anywhere in the world through a clinically supervised digital healthcare platform.

Official Website:

https://evocare.healthcare

The EVOCARE token serves as the core of the ecosystem, supporting:

Digital therapy service payments

Creator support mechanisms

Access to regulated healthcare solutions

By linking real healthcare demand with tokenized utility, EVOCARE creates a sustainable and value-driven ecosystem backed by real-world applications.

Trading Competition Now Live with Trading Competition Details

To celebrate the listing, BiFinance has launched the EVOCARE Trading Competition, allowing users to trade EVOCARE USDT and compete for benefits.

Participants can:

Trade EVOCARE USDT to climb leaderboard rankings

Receive benefits based on trading performance

Unlock additional advantages such as trading additional benefits

The competition is designed to encourage active participation while benefiting both new and experienced traders.

Expanding the RWA and Utility-Driven Ecosystem

The listing of EVOCARE reflects BiFinance’s continued commitment to supporting projects with real-world utility and strong growth potential. By bridging traditional sectors such as healthcare with blockchain infrastructure, BiFinance further strengthens its “virtual + real” ecosystem strategy.

Through ongoing listings, trading campaigns, and ecosystem collaboration, BiFinance aims to provide users with:

High-quality asset access

Enhanced trading opportunities

A more diversified and utility-driven Web3 experience

About BiFinance

BiFinance is a Web3 digital asset trading platform focused on the integration of Real-World Assets (RWA) and blockchain technology. The platform is committed to building a secure, compliant, and scalable financial ecosystem, connecting traditional finance with the decentralized world.

With a growing global presence and continuous innovation in both product and ecosystem design, BiFinance is accelerating the evolution of digital finance through its “Bi+Finance” model.

Media Contact

Organization: BiFinance

Contact Person: Ben

Website: https://www.bifinance.com

Email:
listing@BiFinance.com

Country:Canada

Release id:42777

The post BiFinance Lists EVOCARE-USDT and Launches Trading Competition with Exclusive Rewards appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST